FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362595279> ?p ?o ?g. }

• W4362595279 endingPage "2930" @default.
• W4362595279 startingPage "2930" @default.
• W4362595279 abstract "Abstract Background: Anti-CD47 therapies have demonstrated promising clinical activities; however, expression of CD47 on many different normal human cell types, including RBCs, serves as a large antigen sink for anti-CD47 antibodies. Blocking CD47 on RBCs, such as by magrolimab, has led to anemia, requiring a priming and maintenance dosing schedule in the clinic. ADG153 is a highly differentiated masked anti-CD47 SAFEbody in IgG1 isotype with enhanced ADCC and ADCP functions, in contrast to magrolimab of IgG4 isotype that lacks ADCC and has weaker ADCP effector functions. In normal tissues, the SAFEbody masking moiety is expected to shield ADG153 from binding to CD47; however, in the presence of highly upregulated CD47 in protease-rich tumor microenvironment (TME), the masked antibody can engage dynamically with highly expressed CD47 and can be cleaved, enabling efficient binding to CD47, blocking CD47/SIRPα signaling, and triggering strong anti-tumor activities in solid tumors. Methods: The in vivo anti-tumor efficacy of ADG153 or magrolimab analog (magrolimab) was assessed across several solid tumor xenograft models. Human CD47/SIRPα knock-in mice, harboring CD47-positive xenograft tumors, were used to determine CD47 receptor occupancy (RO) on normal tissues vs. tumors following dosing with ADG153 or magrolimab. Results: ADG153 monotherapy demonstrated strong anti-tumor activities in SCID mice in multiple solid tumor xenograft models, including gastric cancer, SCLC, TNBC, and ovarian cancer models, with mean tumor growth inhibition (TGI) ranging from 75%-99%. Notably, in 2 of these models, the ADG153 efficacy was significantly stronger than that of magrolimab at the same dose level, supporting the importance of IgG1 in introducing ADCC- and ADCP-mediated solid tumor killing effects. In the human CD47/SIRPα knock-in xenograft mouse model, ADG153 and magrolimab dosing resulted in &lt;10% and ~75% CD47 RO on RBCs, respectively. Magrolimab dosing resulted in high RO on normal tissues, but very low RO on tumors. In contrast, ADG153 treatment resulted in low RO on the majority of the normal tissues and RO higher than that achieved by magrolimab on tumors, consistent with the significantly dampened antigen sink liabilities for the masked ADG153. Conclusion: ADG153 demonstrates significantly reduced antigen sink liabilities and favorable CD47 engagement in the TME, which are highly differentiated from other anti-CD47 agents. ADG153 is locally enriched and efficiently cleaved in tumors, engages its target, and elicits potent anti-tumor activities in multiple solid tumor xenograft models. These results indicate that the ADG153 SAFEbody is a novel anti-CD47 IgG1 antibody prodrug with strong ADCC and ADCP capacities and substantially reduced liabilities, supporting its advancement into clinical development. Citation Format: Aaron Nguyen, Peng Zou, Songmao Zheng, Jianfeng Shi, Guizhong Liu, Yan Li, Felix Du, Peter Luo, Jiangchun Xu. ADG153, a novel masked anti-CD47 IgG1 SAFEbody, demonstrates strong in vivo anti-tumor activities in preclinical solid tumor models and preferential CD47 target engagement in the tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2930." @default.
• W4362595279 created "2023-04-06" @default.
• W4362595279 creator A5003058860 @default.
• W4362595279 creator A5004676678 @default.
• W4362595279 creator A5010334212 @default.
• W4362595279 creator A5010898755 @default.
• W4362595279 creator A5023064904 @default.
• W4362595279 creator A5038805449 @default.
• W4362595279 creator A5061919775 @default.
• W4362595279 creator A5068435914 @default.
• W4362595279 creator A5071277762 @default.
• W4362595279 date "2023-04-04" @default.
• W4362595279 modified "2023-09-30" @default.
• W4362595279 title "Abstract 2930: ADG153, a novel masked anti-CD47 IgG1 SAFEbody, demonstrates strong in vivo anti-tumor activities in preclinical solid tumor models and preferential CD47 target engagement in the tumor microenvironment" @default.
• W4362595279 doi "https://doi.org/10.1158/1538-7445.am2023-2930" @default.
• W4362595279 hasPublicationYear "2023" @default.
• W4362595279 type Work @default.
• W4362595279 citedByCount "0" @default.
• W4362595279 crossrefType "journal-article" @default.
• W4362595279 hasAuthorship W4362595279A5003058860 @default.
• W4362595279 hasAuthorship W4362595279A5004676678 @default.
• W4362595279 hasAuthorship W4362595279A5010334212 @default.
• W4362595279 hasAuthorship W4362595279A5010898755 @default.
• W4362595279 hasAuthorship W4362595279A5023064904 @default.
• W4362595279 hasAuthorship W4362595279A5038805449 @default.
• W4362595279 hasAuthorship W4362595279A5061919775 @default.
• W4362595279 hasAuthorship W4362595279A5068435914 @default.
• W4362595279 hasAuthorship W4362595279A5071277762 @default.
• W4362595279 hasConcept C121608353 @default.
• W4362595279 hasConcept C126322002 @default.
• W4362595279 hasConcept C150903083 @default.
• W4362595279 hasConcept C159654299 @default.
• W4362595279 hasConcept C185592680 @default.
• W4362595279 hasConcept C203014093 @default.
• W4362595279 hasConcept C207001950 @default.
• W4362595279 hasConcept C2776107976 @default.
• W4362595279 hasConcept C2780104668 @default.
• W4362595279 hasConcept C3020616263 @default.
• W4362595279 hasConcept C40677261 @default.
• W4362595279 hasConcept C502942594 @default.
• W4362595279 hasConcept C542903549 @default.
• W4362595279 hasConcept C71924100 @default.
• W4362595279 hasConcept C86803240 @default.
• W4362595279 hasConceptScore W4362595279C121608353 @default.
• W4362595279 hasConceptScore W4362595279C126322002 @default.
• W4362595279 hasConceptScore W4362595279C150903083 @default.
• W4362595279 hasConceptScore W4362595279C159654299 @default.
• W4362595279 hasConceptScore W4362595279C185592680 @default.
• W4362595279 hasConceptScore W4362595279C203014093 @default.
• W4362595279 hasConceptScore W4362595279C207001950 @default.
• W4362595279 hasConceptScore W4362595279C2776107976 @default.
• W4362595279 hasConceptScore W4362595279C2780104668 @default.
• W4362595279 hasConceptScore W4362595279C3020616263 @default.
• W4362595279 hasConceptScore W4362595279C40677261 @default.
• W4362595279 hasConceptScore W4362595279C502942594 @default.
• W4362595279 hasConceptScore W4362595279C542903549 @default.
• W4362595279 hasConceptScore W4362595279C71924100 @default.
• W4362595279 hasConceptScore W4362595279C86803240 @default.
• W4362595279 hasIssue "7_Supplement" @default.
• W4362595279 hasLocation W43625952791 @default.
• W4362595279 hasOpenAccess W4362595279 @default.
• W4362595279 hasPrimaryLocation W43625952791 @default.
• W4362595279 hasRelatedWork W2061849361 @default.
• W4362595279 hasRelatedWork W209105756 @default.
• W4362595279 hasRelatedWork W2115013237 @default.
• W4362595279 hasRelatedWork W2593111773 @default.
• W4362595279 hasRelatedWork W2771066073 @default.
• W4362595279 hasRelatedWork W2810541152 @default.
• W4362595279 hasRelatedWork W2887391094 @default.
• W4362595279 hasRelatedWork W3120622096 @default.
• W4362595279 hasRelatedWork W4317779833 @default.
• W4362595279 hasRelatedWork W4362595279 @default.
• W4362595279 hasVolume "83" @default.
• W4362595279 isParatext "false" @default.
• W4362595279 isRetracted "false" @default.
• W4362595279 workType "article" @default.